---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-23-000005"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T19:27:58.089568+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio ends alopecia areata trial; launches Phase 2b for RA and atopic dermatitis

## Summary
- Rosnilimab Phase 2a in alopecia areata failed to achieve target efficacy (no patient SALT<20); further development discontinued.
- Advancing rosnilimab (PD-1 agonist) into global Phase 2b for rheumatoid arthritis; initiates Q3 2023, top-line mid-2025.
- Advancing ANB032 (BTLA agonist) into global Phase 2b for atopic dermatitis; initiates Q2 2023, top-line year-end 2024.
- Cash and investments >$575M as of Dec 31, 2022; estimated ~4-year runway excluding GSK royalties.
- Rosnilimab second Phase 2 trial in undisclosed indication expected by year-end 2023.

## SEC filing metadata
- accession: 0001370053-23-000005
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000005/0001370053-23-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000005/anab-20230105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-23-000005
- JSON: https://secwatch.observer/filing/0001370053-23-000005.json
- Plain text: https://secwatch.observer/filing/0001370053-23-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.